Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 20, 2025 600 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RedirecTT-1 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR ESMO Recommendations on Cancer Care Reflected in Un ECOSOC Ministerial Declaration... August 11, 2025 EMA Recommends Granting a Marketing Authorisation for Retifanlimab February 26, 2024 England moves to a single-dose HPV vaccine June 21, 2023 “Glossy” Awareness Campaigns Weren’t Representing Her Cancer, So She Started #TrueCancerBodies April 24, 2019 Load more HOT NEWS EMA Recommends Extension of Indications for Tislelizumab Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC... Patient-Reported Outcomes Support the Overall Benefit of Trastuzumab Deruxtecan for Patients... News digest – skin cancer deaths, Public Health England plans and...
